Inflammatory Bowel Disease Drugs Market – reveals latest opportunities, trends, projected revenues, and competitive landscape. Read on to determine how you can exploit the impending business opportunities emerging in this sector along with detailed COVID-19 recovery scenarios.
Global inflammatory bowel disease drugs market is projected to reach a market value of US$xxbillion by 2031 with a lucrative CAGR during the forecast period. The growing prevalence of inflammatory bowel disease including Crohn’s disease and ulcerative colitis and growing investment in R&D by pharmaceutical companies are major factor that drives the demand for IBD drugs. Some other key factors that propel the market growth are the growing adoption of drugs for inflammatory bowel disease treatment and maintenance therapy; rising awareness for Crohn’s disease and ulcerative colitis in developing countries; and technological advancements. In addition, the COVID-19 pandemic has a significant impact on the IBD drugs market.
Visiongain’s report shows you the potential revenue streams to 2031, assessing the different segments, major players, qualitative analysis, opportunities trends, and business prospects in the inflammatory bowel disease drugs industry.
How this report will benefit you
Visiongain’s 330+ page report provides 199 tables and 147 charts/graphs. Our new study is envisioned for anyone requiring commercial in-depth analyses for the global IBD drugs market along with detailed segment analysis in the market. Our new study assists you to evaluate the overall global and regional market for IBD drugs. Get the financial analysis of the overall market and different segments including drug class, indication, patient demographics, end-user, and distribution channel and capture higher market share. High opportunity remains in this fast-growing inflammatory bowel disease drugs market. See how to use the existing and upcoming opportunities in this market to gain revenue benefits in the near future. Moreover, the report would help you to improve your strategic decision-making, allows you to frame growth strategies, reinforce the analysis of other market players, and maximise the productivity of the company.
Forecasts to 2031 and other analyses reveal the commercial prospects
• Our new study provides you with revenue forecast by different segments including drug class, indication, and distribution channel to 2031
• It also includes growth rates for different 4 regional markets along with 11 countries and COVID-19 impact analysis on each market
• The profiles of the top 13 companies are very descriptive and comprehensive data including company snapshot, overview, commercial developments, company market shares, and detailed financial analysis with revenue and other financials
• The COVID-19 has a positive impact on the IBD drugs industry and the report includes detailed analysis and invaluable insight into how COVID-19 will affect the industry.
Discover sales forecasts for the global and regional market forecasts from 2021-2031
Along with revenue prediction for the overall global inflammatory bowel disease market, there is segmentation by region for 4 regional markets including the U.S., Japan, Europe5, BRIC, and RoW and 11 major countries.
To access the data contained in this document please email contactus@visiongain.com
Global Inflammatory Bowel Disease Drugs Market Revenue and Growth Forecasts from 2021 to 2031 By Drug Class
• Biologics
• Aminosalicylates
• Corticosteroids
• Antibiotics
• Immunomodulators
• Others
Global Inflammatory Bowel Disease Drugs Market Revenue and Growth Forecasts from 2021 to 2031 By Indication
• Crohn’s Disease
• Ulcerative Colitis
Global Inflammatory Bowel Disease Drugs Market Revenue and Growth Forecasts from 2021 to 2031 By Distribution Channel
• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
Regional market revenue and growth forecasts from 2021 to 2031:
• U.S.
• Japan
• Europe5
• Germany
• UK
• France
• Italy
• Spain
• BRIC
• Brazil
• Russia
• India
• China
• RoW
Need industry data? Please contact us today.
Detailed profiles of 13 leading companies that are operating in the market
The report includes profiles of 13 major companies involved in the IBD drugs market. The companies profiled in this report include: AbbVie, Janssen Biotech, Allergan plc., Takeda Pharmaceuticals, Pfizer Inc., Novartis AG, UCB Pharma S.A., Biogen Inc., Gilead Sciences, Inc., F. Hoffmann-La Roche AG, Celgene Corporation, Celltrion Corporation, and Ferring B.V.
Find qualitative and quantitative analyses with independent predictions. Receive information that only our report contains, staying informed with this invaluable business intelligence.
In summary, our 330+ page report delivers you with the following knowledge:
• Revenue forecasts from 2021 to 2031 for the global IBD drugs market and subsegments (by drug class, indication, distribution channel, and region)– discover the industry’s prospects, finding the most lucrative areas for investments and revenue generation
• Detailed profiles of top 13 IBD drugs manufacturers, with financial overviews
• Revenue forecasts from 2021 to 2031 for 4 regional markets – See forecasts for the IBD drugs market in the U.S., Japan, Europe5, BRIC, and RoW.
Information found nowhere else
With this new and exclusive report, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your investment, research, analyses, and decisions. Visiongain’s study is for everybody needing commercial analyses for the IBD drugs market and detailed analysis of COVID-19 impact. You will get the most recent data, opportunities, trends, and predictions.
The Inflammatory Bowel Disease Drugs Market Forecast 2021-2031 will be of value to anyone who wants to better understand the market and its various segments. It would be valuable for companies that desire to better understand the part of the industry they are involved in, or those coveting to expand or enter into a different regional market or to understand strategic analysis of leading companies of the IBD drugs industry.
To access the data contained in this document please email contactus@visiongain.com
Buy our report today Inflammatory Bowel Diseases (IBD) Drug Market Report to 2031: Forecasts by Drug Class (Biologics, Aminosalicylates, Corticosteroids, Antibiotics, Immunomodulators, Others), by Indication (Crohn’s Disease, Ulcerative Colitis), by Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy) AND Regional and Leading National Market Analysis PLUS Analysis of Leading IBD Drug Companies AND COVID-19 Recovery Scenarios. Avoid missing out by staying informed – order our report now.
Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6
Do you have any custom requirements we can help you with? Any need for a specific country, geo region, market segment or specific company information? Contact us today, we can discuss your needs and see how we can help: sara.peerun@visiongain.com
1. Report Overview
1.1. World Inflammatory Bowel Disease Drugs (IBD) Market: Overview of Findings
1.2. Global Inflammatory Bowel Disease Drugs Market Segmentation
1.3. Why You Should Read This Report
1.1 Main Questions Covered in the Analysis
1.4. What This Report Delivers
1.5. Key Questions Answered By This Analytical Report Include:
1.6. Who is This Report For?
1.7. Methodology
1.1.1 Primary Research
1.1.2 Secondary Research
1.1.3 Market Evaluation and Forecasting Methods
1.8. COVID-19 Impact: Recovery Scenarios
1.9. Frequently Asked Questions (FAQs)
1.10. Associated Visiongain Reports
1.11. About Visiongain
2 Executive Summary
3 Introduction to the Inflammatory Bowel Disease Drug Market
3.1 What is Inflammatory Bowel Disease (IBD)?
3.2 Classification of IBD
3.3 Symptoms and Diagnosis of IBD
3.4 Multifactorial Causes of IBD
3.5 How common is IBD?
3.6 What Are the Treatment Options for IBD?
3.6.1 Aminosalicylates – The Most Common Therapy
3.6.2 Antibiotics – Supporting Evidences
3.6.3 Corticosteroids – growth is majorly driven by Uceris
3.6.4 Immunomodulators – Slow to Act?
3.6.5 Biologics – Not Cost-effective?
3.7 Treatment Goals for IBD – Treat-to-Target Approach?
3.8 Treatment Algorithm
3.9 Management of Inflammatory Bowel Disease – 2020
4 Market Dynamics
4.1 Drivers Analysis – Inflammatory Bowel Disease Drugs Market
4.1.1 Increasing Disease Incidence in Most National Markets
4.1.2 Better Diagnosis of IBD
4.1.3 Delivery Systems Improve Existing Drugs of IBD
4.2 Opportunity Analysis – Inflammatory Bowel Disease Drugs Market
4.2.1 Biological Drugs – Driving the Market Significantly
4.2.2 Socioeconomic Costs of IBD
4.3 Restrains Analysis – Inflammatory Bowel Disease Drugs Market
4.3.1 Lack of Understanding of Disease Aetiology
4.3.2 Compliance – Frequent Dosing is Inconvenient
4.3.3 Limitations of Biologics – Side Effect Profiles
4.4 Challenges Analysis – Inflammatory Bowel Disease Drugs Market
4.4.1 The Possible Development of Alternative Treatments
4.4.2 Surgery – Treatment for Recalcitrant IBD
4.4.3 Health Care Cost Containment
4.5 Porter’s Five Forces Analysis – Inflammatory Bowel Disease Drugs Market
4.5.1 Bargaining Power of Supplier: Low
4.5.2 Bargaining Power of Buyer: Moderate
4.5.3 Competitive Rivalry: High
4.5.4 Threat of New Entrants: High
4.5.5 Threat of Substitutes: High
4.6 SWOT Analysis – Inflammatory Bowel Disease Drugs Market
4.6.1 Strengths
4.6.2 Weaknesses
4.6.3 Opportunities
4.6.4 Threats
4.7 PEST Analysis – Inflammatory Bowel Disease Drugs Market
4.7.1 Political
4.7.2 Economical
4.7.3 Social
4.7.4 Technological
5 Global Inflammatory Bowel Diseases Drug Market, 2021-2031
5.1 Global Inflammatory Bowel Disease Drugs Market: COVID-19 Recovery Forecasts (V, U, W, L) 2021-2031
5.1.1 "V" shaped Recovery - Rapid Decline - Sharp Borrow -Rapid Recovery
5.1.2 "U" Shaped Recovery -Rapid Decline Early Then Slow - Gradual at the Bottom - Slow Recovery at First - Faster Recovery Later On
5.1.3 "W" Shaped Recovery -Rapid Decline - Rapid Recovery- Return of Virus - Another Sharp Decline -Recovery
5.1.4 "L" Shaped Recovery - Rapid Decline - Then Slow Growth
6 Global Inflammatory Bowel Diseases Drug Market by Indication, 2021-2031
6.1 Global Inflammatory Bowel Disease Drugs Market for Crohn’s Disease Segment: Revenue Forecast 2021-2031
6.1.1 Recovery Forecasts (V, U, W, L)
6.2 Global Inflammatory Bowel Disease Drugs Market for Ulcerative Colitis Segment: Revenue Forecast 2021-2031
6.2.1 Recovery Forecasts (V, U, W, L)
7 Global Inflammatory Bowel Disease Drugs Market Size Forecast 2021-2031 by Drug Class
7.1 Global Inflammatory Bowel Disease Drugs Market for Biologics Segment: Revenue Forecast 2021-2031
7.2 Biologic Therapies Forecast 2021-2031 – Largest Revenue Grossing Segment
7.2.1 Recovery Forecasts (V,U, W, L)
7.3 Aminosalicylates Forecast 2021-2031: The Steady Growth
7.3.1 Recovery Forecasts (V,U, W, L)
7.4 Corticosteroids Forecast 2021-2031: Rescue therapies
7.4.1 Recovery Forecasts (V,U, W, L)
7.5 Antibiotics Forecast 2021-2031: Growing Despite Challenges
7.5.1 Recovery Forecasts (V,U, W, L)
7.6 Immunomodulators Forecast 2021-2031 – Will Grow at Moderate Pace
7.6.1 Recovery Forecasts (V,U, W, L)
7.7 Other Drug Classes Segment Forecast 2021-2031 – Will Grow at a Significant Rate
7.7.1 Recovery Forecasts (V,U, W, L)
8 Global Inflammatory Bowel Disease by Distribution Channel, 2021-2031
8.1 Hospital Pharmacies Forecast 2021-2031
8.1.1 Recovery Forecasts (V,U, W, L)
8.2 Retail Pharmacies Forecast 2021-2031
8.2.1 Recovery Forecasts (V,U, W, L)
8.3 Online Pharmacies Forecast 2021-2031
8.3.1 Recovery Forecasts (V,U, W, L)
9 Leading National Markets: Sales Outlooks, 2021- 2031
9.1 Global Inflammatory Bowel Disease Drugs Market Overview: Regional Distribution, 2021- 2031
9.2 Inflammatory Bowel Disease Drugs - Leading National Markets 2020
9.3 The US IBD Drugs Market, 2021-2031 – The World Leader in the Inflammatory Bowel Disease Drugs Market
9.3.1 COVID-19 Market Recovery for US Inflammatory Bowel Disease Drugs Market: "V" shaped Recovery 2021- 2031
9.3.2 COVID-19 Market Recovery for US Inflammatory Bowel Disease Drugs Market: "U" shaped Recovery 2021- 2031
9.3.3 COVID-19 Market Recovery for US Inflammatory Bowel Disease Drugs Market: "W" shaped Recovery 2021 – 2031
9.3.4 COVID-19 Market Recovery for US Inflammatory Bowel Disease Drugs Market: "L" shaped Recovery 2021- 2031
9.3.5 U.S. IBD Drugs Market By Drug Class, 2021-2031
9.3.6 U.S. IBD Drugs Market By Indication, 2021-2031
9.3.7 U.S. IBD Drugs Market By Distribution Channel, 2021-2031
9.4 The Japanese IBD Drugs Market, 2021-2031- Developed Healthcare Infrastructure is Expected to Boost the Market Growth
9.4.1 COVID-19 Market Recovery for Japan Inflammatory Bowel Disease Drugs Market: "V" shaped Recovery 2021- 2031
9.4.2 COVID-19 Market Recovery for Japan Inflammatory Bowel Disease Drugs Market: "U" shaped Recovery 2021- 2031
9.4.3 COVID-19 Market Recovery for Japan Inflammatory Bowel Disease Drugs Market: "W" shaped Recovery 2021 – 2031
9.4.4 COVID-19 Market Recovery for Japan Inflammatory Bowel Disease Drugs Market: "L" shaped Recovery 2021- 2031
9.4.5 Japan IBD Drugs Market By Drug Class, 2021-2031
9.4.6 Japan IBD Drugs Market By Indication, 2021-2031
9.4.7 Japan IBD Drugs Market By Distribution Channel, 2021-2031
9.5 The EU5 IBD Drugs Market, 2021-2031
9.5.1 COVID-19 Market Recovery for EU5 Inflammatory Bowel Disease Drugs Market: "V" shaped Recovery 2021- 2031
9.5.2 COVID-19 Market Recovery for EU5 Inflammatory Bowel Disease Drugs Market: "U" shaped Recovery 2021- 2031
9.5.3 COVID-19 Market Recovery for EU5 Inflammatory Bowel Disease Drugs Market: "W" shaped Recovery 2021 – 2031
9.5.4 COVID-19 Market Recovery for EU5 Inflammatory Bowel Disease Drugs Market: "L" shaped Recovery 2021- 2031
9.5.5 EU5 IBD Drugs Market By Drug Class, 2021-2031
9.5.6 EU5 IBD Drugs Market By Indication, 2021-2031
9.5.7 EU5 IBD Drugs Market By Distribution Channel, 2021-2031
9.5.8 Germany Inflammatory Bowel Disease Drugs Market, 2021- 2031
9.5.8.1 Germany Accounted For The Largest Revenue Share In The EU5 Inflammatory Bowel Disease Drugs Market
9.5.8.2 Presence of Well-Established Healthcare Infrastructure
9.5.9 UK Inflammatory Bowel Disease Drugs Market, 2021- 2031
9.5.9.1 Increasing Prevalence Of IBD In The UK Is Driving The Demand Of Advanced Drugs
9.5.9.2 Growing Awareness For The IBD Among People
9.5.10 France Inflammatory Bowel Disease Drugs Market, 2021- 2031
9.5.10.1 Availability Of Advanced Healthcare In This Region Will Propel The Demand For Inflammatory Bowel Disease Drugs
9.5.10.2 Growing Research Funding Is Boosting The French Market
9.5.11 Italy Inflammatory Bowel Disease Drugs Market, 2021- 2031
9.5.11.1 One Of The Fastest Growing Market In EU5 Region
9.5.11.2 Growing Number Of Product Launches Will Boost The Regional Market Growth
9.5.12 Spain Inflammatory Bowel Disease Drugs Market, 2021- 2031
9.5.12.1 Rising Prevalence Of IBD In This Region Will Drive The Spain Market Growth
9.5.12.2 Rising Number Healthcare Awareness Programs By The Government
9.6 The BRIC IBD Drugs Market, 2021-2031 – Fastest Growing Region in the Global IBD Market
9.6.1 COVID-19 Market Recovery for BRIC Inflammatory Bowel Disease Drugs Market: "V" shaped Recovery 2021- 2031
9.6.2 COVID-19 Market Recovery for BRIC Inflammatory Bowel Disease Drugs Market: "U" shaped Recovery 2021- 2031
9.6.3 COVID-19 Market Recovery for BRIC Inflammatory Bowel Disease Drugs Market: "W" shaped Recovery 2021 – 2031
9.6.4 COVID-19 Market Recovery for BRIC Inflammatory Bowel Disease Drugs Market: "L" shaped Recovery 2021- 2031
9.6.5 BRIC IBD Drugs Market By Drug Class, 2021-2031
9.6.6 BRIC IBD Drugs Market By Indication, 2021-2031
9.6.7 BRIC IBD Drugs Market By Distribution Channel, 2021-2031
9.6.8 Brazil Inflammatory Bowel Disease Drugs Market, 2021- 2031
9.6.8.1 Developing Healthcare Infrastructure Is Expected To Have Positive Impact On The Regional Market Growth
9.6.8.2 Medical Tourism In Brazil Will Have Positive Impact On The Regional Market Growth
9.6.9 Russia Inflammatory Bowel Disease Drugs Market, 2021- 2031
9.6.9.1 Increasing investment by the government on healthcare infrastructure is a major factor that will boost the market growth
9.6.9.2 Rising Awareness For IBD Among Healthcare Professionals And People
9.6.10 India Inflammatory Bowel Disease Drugs Market, 2021- 2031
9.6.10.1 One of the fastest growing market in BRIC region
9.6.10.2 Developing Infrastructure In India
9.6.11 China Inflammatory Bowel Disease Drugs Market, 2021- 2031
9.6.11.1 Fastest Growing Region In The Global IBD Market
9.6.11.2 Presence Of Leading Manufacturers In This Region
10 The R&D Pipeline for Inflammatory Bowel Diseases
10.1 Top Marketed and pipeline products – Launch dates and Patent expiry
10.2 Interleukin (IL) Inhibitors – One of the Main Areas of Innovation
10.2.1 STI-0529, Sublimity Therapeutics (formerly CyCol, Sigmoid Pharma)
10.2.2 PF-04236921 (Pfizer)
10.2.3 QAX 576 (Novartis)
10.2.4 TNF Kinoid (Neovacs)
10.2.5 Vidofludimus (4SC) – Suspended
10.2.6 Stelara (Ustekinumab, CNTO 1275, Janssen Biotech)
10.2.7 Entyvio (Vedolizumab, Takeda)
10.2.8 Risankizumab, Abbvie and Boehringer Ingelheim
10.2.9 Brazikumab, Allergan (Under collaboration agreement with AstraZeneca & Amgen)
10.3 Cell-Adhesion Molecule (CAM) Inhibitors – A Promising Avenue
10.3.1 AJG 511 (Ajinomoto Pharmaceutical Co.)
10.3.2 AJM 300 (Ajinomoto Pharmaceuticals)
10.3.3 MEDI 7183/AMG 181 (AstraZeneca)
10.3.4 Etrolizumab (Roche)
10.3.5 PF-00547659 (Pfizer)
10.3.6 Alicaforsen (ISIS 2302, Atlantic Healthcare)
10.3.7 MEDI-2070/AMG 139 (AstraZeneca & Amgen)
10.4 TNF-α Inhibitors – a Specific Target
10.4.1 AVX-470 (Avaxia Biologics)
10.4.2 Ozoralizumab (ALX-0061, Ablynx)
10.5 Stem Cell Therapies – Basis for a Cure?
10.5.1 Ovasave (TxCell)
10.5.2 MultiStem (Athersys and Pfizer)
10.5.3 Prochymal (Remestemcel-L, Osiris Therapeutics)
10.5.4 Cx601 (TiGenix)
10.6 JAK Inhibitors – New Target Pathway
10.6.1 JNJ-54781532 (Janssen)
10.6.2 Xeljanz, (Tofacitinib, CP-690550, Pfizer)
10.7 Toll-like Receptor Agonists
10.7.1 BL-7040 (BioLineRX)
10.7.2 Kappaproct (InDex Pharmaceuticals)
10.8 Other Classes of Agent
10.8.1 Trichuris suis ova (CNDO-201, Coronado Biosciences)
10.8.2 GLPG0974 (Galapagos)
10.8.3 RPC1063 (Receptos/now Celgene)
10.8.4 SGX203 (Soligenix)
10.8.5 Mongersen (GED-0301, Celgene)
10.8.6 Tetomilast (OPC-6535, Otsuka)
10.8.7 Laquinimod (Active Biotech)
10.8.8 RHB-104 (RedHill Biopharma)
10.8.9 Ozanimod (Celgene)
10.8.10 GED-0301 (Celgene)
10.9 Biosimilar Candidates – Promising Competitors of Leading Biologics
10.9.1 Adalimumab Biosimilars
10.9.2 Infliximab Biosimilars
11 Leading Companies in the IBD Pharmaceuticals Market
11.1 Company Share Analysis
11.2 Strategic Developments, 2017-2020
11.3 Abbvie
11.3.1 Company Information
11.3.2 Business Overview
11.3.3 Pipeline Overview
11.3.4 Product Portfolio
11.3.5 Recent Developments, 2017-2020
11.4 Janssen Biotech
11.4.1 Company Information, 2020
11.4.2 Business Overview
11.4.3 Pipeline Overview
11.4.4 Product Portfolio
11.4.5 Recent Developments, 2017-2020
11.5 Allergan plc
11.5.1 Company Information, 2020
11.5.2 Business Overview
11.5.3 Pipeline Overview:
11.5.4 Product Portfolio
11.5.5 Recent Developments, 2017-2020
11.6 Takeda Pharmaceuticals
11.6.1 Company Information, 2020
11.6.2 Business Overview
11.6.3 Pipeline Overview
11.6.4 Product Portfolio
11.6.5 Recent Developments, 2017-2020
11.7 Pfizer
11.7.1 Company Information, 2020
11.7.2 Business Overview
11.7.3 Pipeline Overview
11.7.4 Product Portfolio
11.7.5 Recent Developments, 2017-2020
11.8 Novartis AG
11.8.1 Company Information, 2020
11.8.2 Business Overview
11.8.3 Pipeline Overview
11.8.4 Product Portfolio
11.8.5 Recent Developments, 2017-2020
11.9 UCB Pharma S.A.
11.9.1 Company Information, 2020
11.9.2 Business Overview
11.9.3 Pipeline Overview
11.9.4 Product Portfolio
11.10 Biogen Inc.
11.10.1 Company Information, 2020
11.10.2 Business Overview
11.10.3 Product Portfolio
11.11 Gilead Sciences, Inc.
11.11.1 Company Information, 2020
11.11.2 Business Overview
11.11.3 Pipeline Overview
11.11.4 Product Portfolio
11.12 Roche
11.12.1 Company Information, 2020
11.12.2 Business Overview
11.12.3 Pipeline Overview
11.12.4 Recent Developments, 2017-2020
11.13 Celgene Corporation
11.13.1 Company Information, 2020
11.13.2 Business Overview
11.13.3 Pipeline Overview
11.13.4 Product Portfolio
11.13.5 Recent Developments, 2017-2020
11.14 Celltrion Corporation
11.14.1 Company Information, 2020
11.14.2 Pipeline Overview
11.14.3 Product Portfolio
11.15 Ferring B.V.
11.15.1 Company Information, 2020
11.15.2 Business Overview
11.15.3 Product Portfolio
12 Conclusions & Recommendations
12.1 Conclusion
12.2 Recommendations
List of Tables
Table 1 Global Inflammatory Bowel Disease Drugs Market, 2020 & 2031 (US$billion, CAGR%)
Table 2 Differentiating Crohn’s Disease and Ulcerative Colitis
Table 3 Clinical Presentation Crohn’s Disease and Ulcerative Colitis
Table 4 Worldwide Prevalence Rates for IBD, 2020-2020
Table 5 Worldwide Incidence Rates for IBD, 2020-2020 (Newly diagnosed cases per 100,000 person-years)
Table 6 Geographical Variations in the Incidence of IBD, 2020
Table 7 Treatment Recommendations for IBD
Table 8 Medical Approach for IBD Management, 2020
Table 9 Indications
Table 10 Other Drug Types Used to Treat IBD, 2020
Table 11 Aminoacylates for IBD Management, 2020
Table 12 Antibiotics for IBD Management, 2020
Table 13 Immunomodulators for IBD Management, 2020
Table 14 Biologics for IBD Management, 2020
Table 15 Global Inflammatory Bowel Disease Drugs Market, Revenue Forecast 2021-2031 (US$billion, AGR%, CAGR%)
Table 16 “V” Shaped Recovery: Global Inflammatory Bowel Disease Drugs Market, Revenue Forecast 2021-2031 (US$billion, AGR%, CAGR%)
Table 17 “U” Shaped Recovery: Global Inflammatory Bowel Disease Drugs Market, Revenue Forecast 2021-2031 (US$billion, AGR%, CAGR%)
Table 18 “W” Shaped Recovery: Global Inflammatory Bowel Disease Drugs Market, Revenue Forecast 2021-2031 (US$billion, AGR%, CAGR%)
Table 19 “L” Shaped Recovery: Global Inflammatory Bowel Disease Drugs Market, Revenue Forecast 2021-2031 (US$billion, AGR%, CAGR%)
Table 20 Global Inflammatory Bowel Disease Drugs Market Forecast by Indication, 2021-2031 (US$billion, AGR%, CAGR%)
Table 21 Global Inflammatory Bowel Disease Drugs Market for Crohn’s Disease Segment: Revenue Forecast 2021-2031 (US$billion, AGR%, CAGR%)
Table 22 “V” Shaped Recovery: Global Inflammatory Bowel Disease Drugs Market for Crohn’s Disease Segment, Revenue Forecast 2021-2031 (US$billion, AGR%, CAGR%)
Table 23 “U” Shaped Recovery: Global Inflammatory Bowel Disease Drugs Market for Crohn’s Disease Segment, Revenue Forecast 2021-2031 (US$billion, AGR%, CAGR%)
Table 24 “W” Shaped Recovery: Global Inflammatory Bowel Disease Drugs Market for Crohn’s Disease Segment, Revenue Forecast 2021-2031 (US$billion, AGR%, CAGR%)
Table 25 “L” Shaped Recovery: Global Inflammatory Bowel Disease Drugs Market for Crohn’s Disease Segment, Revenue Forecast 2021-2031 (US$billion, AGR%, CAGR%)
Table 26 Global Inflammatory Bowel Disease Drugs Market for Ulcerative Colitis Segment: Revenue Forecast 2021-2031 (US$billion, AGR%, CAGR%)
Table 27 “V” Shaped Recovery: Global Inflammatory Bowel Disease Drugs Market for Ulcerative Colitis Segment, Revenue Forecast 2021-2031 (US$billion, AGR%, CAGR%)
Table 28 “U” Shaped Recovery: Global Inflammatory Bowel Disease Drugs Market for Ulcerative Colitis Segment, Revenue Forecast 2021-2031 (US$billion, AGR%, CAGR%)
Table 29 “W” Shaped Recovery: Global Inflammatory Bowel Disease Drugs Market for Ulcerative Colitis Segment, Revenue Forecast 2021-2031 (US$billion, AGR%, CAGR%)
Table 30 “L” Shaped Recovery: Global Inflammatory Bowel Disease Drugs Market for Ulcerative Colitis Segment, Revenue Forecast 2021-2031 (US$billion, AGR%, CAGR%)
Table 31 Global Inflammatory Bowel Disease Drugs Market Forecast by Drug Class, 2021-2031 (US$billion, AGR%, CAGR%)
Table 32 Global Inflammatory Bowel Disease Drugs Market for Biologics Segment: Revenue Forecast 2021-2031 (US$billion, AGR%, CAGR%)
Table 33 “V” Shaped Recovery: Global Inflammatory Bowel Disease Drugs Market for Biologics Segment, Revenue Forecast 2021-2031 (US$billion, AGR%, CAGR%)
Table 34 “U” Shaped Recovery: Global Inflammatory Bowel Disease Drugs Market for Biologics Segment, Revenue Forecast 2021-2031 (US$billion, AGR%, CAGR%)
Table 35 “W” Shaped Recovery: Global Inflammatory Bowel Disease Drugs Market for Biologics Segment, Revenue Forecast 2021-2031 (US$billion, AGR%, CAGR%)
Table 36 “L” Shaped Recovery: Global Inflammatory Bowel Disease Drugs Market for Biologics Segment, Revenue Forecast 2021-2031 (US$billion, AGR%, CAGR%)
Table 37 Global Inflammatory Bowel Disease Drugs Market for Aminosalicylates Segment: Revenue Forecast 2021-2031 (US$billion, AGR%, CAGR%)
Table 38 “V” Shaped Recovery: Global Inflammatory Bowel Disease Drugs Market for Aminosalicylates Segment, Revenue Forecast 2021-2031 (US$billion, AGR%, CAGR%)
Table 39 “U” Shaped Recovery: Global Inflammatory Bowel Disease Drugs Market for Aminosalicylates Segment, Revenue Forecast 2021-2031 (US$billion, AGR%, CAGR%)
Table 40 “W” Shaped Recovery: Global Inflammatory Bowel Disease Drugs Market for Aminosalicylates Segment, Revenue Forecast 2021-2031 (US$billion, AGR%, CAGR%)
Table 41 “L” Shaped Recovery: Global Inflammatory Bowel Disease Drugs Market for Aminosalicylates Segment, Revenue Forecast 2021-2031 (US$billion, AGR%, CAGR%)
Table 42 Global Inflammatory Bowel Disease Drugs Market for Corticosteroids Segment: Revenue Forecast 2021-2031 (US$billion, AGR%, CAGR%)
Table 43 “V” Shaped Recovery: Global Inflammatory Bowel Disease Drugs Market for Corticosteroids Segment, Revenue Forecast 2021-2031 (US$billion, AGR%, CAGR%)
Table 44 “U” Shaped Recovery: Global Inflammatory Bowel Disease Drugs Market for Corticosteroids Segment, Revenue Forecast 2021-2031 (US$billion, AGR%, CAGR%)
Table 45 “W” Shaped Recovery: Global Inflammatory Bowel Disease Drugs Market for Corticosteroids Segment, Revenue Forecast 2021-2031 (US$billion, AGR%, CAGR%)
Table 46 “L” Shaped Recovery: Global Inflammatory Bowel Disease Drugs Market for Corticosteroids Segment, Revenue Forecast 2021-2031 (US$billion, AGR%, CAGR%)
Table 47 Global Inflammatory Bowel Disease Drugs Market for Antibiotics Segment: Revenue Forecast 2021-2031 (US$billion, AGR%, CAGR%)
Table 48 “V” Shaped Recovery: Global Inflammatory Bowel Disease Drugs Market for Antibiotics Segment, Revenue Forecast 2021-2031 (US$billion, AGR%, CAGR%)
Table 49 “U” Shaped Recovery: Global Inflammatory Bowel Disease Drugs Market for Antibiotics Segment, Revenue Forecast 2021-2031 (US$billion, AGR%, CAGR%)
Table 50 “W” Shaped Recovery: Global Inflammatory Bowel Disease Drugs Market for Antibiotics Segment, Revenue Forecast 2021-2031 (US$billion, AGR%, CAGR%)
Table 51 “L” Shaped Recovery: Global Inflammatory Bowel Disease Drugs Market for Antibiotics Segment, Revenue Forecast 2021-2031 (US$billion, AGR%, CAGR%)
Table 52 Global Inflammatory Bowel Disease Drugs Market for Immunomodulators Segment: Revenue Forecast 2021-2031 (US$billion, AGR%, CAGR%)
Table 53 “V” Shaped Recovery: Global Inflammatory Bowel Disease Drugs Market for Immunomodulators Segment, Revenue Forecast 2021-2031 (US$billion, AGR%, CAGR%)
Table 54 “U” Shaped Recovery: Global Inflammatory Bowel Disease Drugs Market for Immunomodulators Segment, Revenue Forecast 2021-2031 (US$billion, AGR%, CAGR%)
Table 55 “W” Shaped Recovery: Global Inflammatory Bowel Disease Drugs Market for Immunomodulators Segment, Revenue Forecast 2021-2031 (US$billion, AGR%, CAGR%)
Table 56 “L” Shaped Recovery: Global Inflammatory Bowel Disease Drugs Market for Immunomodulators Segment, Revenue Forecast 2021-2031 (US$billion, AGR%, CAGR%)
Table 57 Global Inflammatory Bowel Disease Drugs Market for Others Segment: Revenue Forecast 2021-2031 (US$billion, AGR%, CAGR%)
Table 58 “V” Shaped Recovery: Global Inflammatory Bowel Disease Drugs Market for Others Segment, Revenue Forecast 2021-2031 (US$billion, AGR%, CAGR%)
Table 59 “U” Shaped Recovery: Global Inflammatory Bowel Disease Drugs Market for Others Segment, Revenue Forecast 2021-2031 (US$billion, AGR%, CAGR%)
Table 60 “W” Shaped Recovery: Global Inflammatory Bowel Disease Drugs Market for Others Segment, Revenue Forecast 2021-2031 (US$billion, AGR%, CAGR%)
Table 61 “L” Shaped Recovery: Global Inflammatory Bowel Disease Drugs Market for Others Segment, Revenue Forecast 2021-2031 (US$billion, AGR%, CAGR%)
Table 62 Global Inflammatory Bowel Disease by Distribution Channel Forecast: Revenues (US$bn), AGR (%), CAGR (%), 2021-2031
Table 63 Global Inflammatory Bowel Disease Drugs Market for Hospital Pharmacies Segment: Revenue Forecast 2021-2031 (US$billion, AGR%, CAGR%)
Table 64 “V” Shaped Recovery: Global Inflammatory Bowel Disease Drugs Market for Hospital Pharmacies Segment, Revenue Forecast 2021-2031 (US$billion, AGR%, CAGR%)
Table 65 “U” Shaped Recovery: Global Inflammatory Bowel Disease Drugs Market for Hospital Pharmacies Segment, Revenue Forecast 2021-2031 (US$billion, AGR%, CAGR%)
Table 66 “W” Shaped Recovery: Global Inflammatory Bowel Disease Drugs Market for Hospital Pharmacies Segment, Revenue Forecast 2021-2031 (US$billion, AGR%, CAGR%)
Table 67 “L” Shaped Recovery: Global Inflammatory Bowel Disease Drugs Market for Hospital Pharmacies Segment, Revenue Forecast 2021-2031 (US$billion, AGR%, CAGR%)
Table 68 Global Inflammatory Bowel Disease Drugs Market for Retail Pharmacies Segment: Revenue Forecast 2021-2031 (US$billion, AGR%, CAGR%)
Table 69 “V” Shaped Recovery: Global Inflammatory Bowel Disease Drugs Market for Retail Pharmacies Segment, Revenue Forecast 2021-2031 (US$billion, AGR%, CAGR%)
Table 70 “U” Shaped Recovery: Global Inflammatory Bowel Disease Drugs Market for Retail Pharmacies Segment, Revenue Forecast 2021-2031 (US$billion, AGR%, CAGR%)
Table 71 “W” Shaped Recovery: Global Inflammatory Bowel Disease Drugs Market for Retail Pharmacies Segment, Revenue Forecast 2021-2031 (US$billion, AGR%, CAGR%)
Table 72 “L” Shaped Recovery: Global Inflammatory Bowel Disease Drugs Market for Retail Pharmacies Segment, Revenue Forecast 2021-2031 (US$billion, AGR%, CAGR%)
Table 73 Global Inflammatory Bowel Disease Drugs Market for Online Pharmacies Segment: Revenue Forecast 2021-2031 (US$billion, AGR%, CAGR%)
Table 74 “V” Shaped Recovery: Global Inflammatory Bowel Disease Drugs Market for Online Pharmacies Segment, Revenue Forecast 2021-2031 (US$billion, AGR%, CAGR%)
Table 75 “U” Shaped Recovery: Global Inflammatory Bowel Disease Drugs Market for Online Pharmacies Segment, Revenue Forecast 2021-2031 (US$billion, AGR%, CAGR%)
Table 76 “W” Shaped Recovery: Global Inflammatory Bowel Disease Drugs Market for Online Pharmacies Segment, Revenue Forecast 2021-2031 (US$billion, AGR%, CAGR%)
Table 77 “L” Shaped Recovery: Global Inflammatory Bowel Disease Drugs Market for Online Pharmacies Segment, Revenue Forecast 2021-2031 (US$billion, AGR%, CAGR%)
Table 78 IBD Drugs Market Forecast by Regional Overview (US$bn), 2021-2031
Table 79 US IBD Drugs Market Forecast: Revenues (US$bn), AGR (%), CAGR (%), 2021-2031
Table 80 US IBD Forecast, “V” Shaped COVID-19 Recovery: Revenues (US$bn), AGR (%), CAGR (%), 2021-2031
Table 81 US IBD Forecast, “U” Shaped COVID-19 Recovery: Revenues (US$bn), AGR (%), CAGR (%), 2021-2031
Table 82 US IBD Forecast, “W” Shaped COVID-19 Recovery: Revenues (US$bn), AGR (%), CAGR (%), 2021-2031
Table 83 US IBD Forecast, “L” Shaped COVID-19 Recovery: Revenues (US$bn), AGR (%), CAGR (%), 2021-2031
Table 84 U.S. Inflammatory Bowel Disease Drugs Market Forecast by Drug Class, 2021-2031 (US$billion, AGR%, CAGR%)
Table 85 U.S. Inflammatory Bowel Disease Drugs Market Forecast by Indication, 2021-2031 (US$billion, AGR%, CAGR%)
Table 86 U.S. Inflammatory Bowel Disease by Distribution Channel Forecast: Revenues (US$bn), AGR (%), CAGR (%), 2021-2031
Table 87 Japanese IBD Drugs Market Forecast: Revenues (US$bn), AGR (%), CAGR (%), 2021-2031
Table 88 Japan IBD Forecast, “V” Shaped COVID-19 Recovery: Revenues (US$bn), AGR (%), CAGR (%), 2021-2031
Table 89 Japan IBD Forecast, “U” Shaped COVID-19 Recovery: Revenues (US$bn), AGR (%), CAGR (%), 2021-2031
Table 90 Japan IBD Forecast, “W” Shaped COVID-19 Recovery: Revenues (US$bn), AGR (%), CAGR (%), 2021-2031
Table 91 Japan IBD Forecast, “L” Shaped COVID-19 Recovery: Revenues (US$bn), AGR (%), CAGR (%), 2021-2031
Table 92 Japan Inflammatory Bowel Disease Drugs Market Forecast by Drug Class, 2021-2031 (US$billion, AGR%, CAGR%)
Table 93 Japan Inflammatory Bowel Disease Drugs Market Forecast by Indication, 2021-2031 (US$billion, AGR%, CAGR%)
Table 94 Japan Inflammatory Bowel Disease by Distribution Channel Forecast: Revenues (US$bn), AGR (%), CAGR (%), 2021-2031
Table 95 EU5 IBD Drugs Market Forecast: Revenues (US$bn), AGR (%), CAGR (%), 2021-2031
Table 96 EU5 IBD Forecast, “V” Shaped COVID-19 Recovery: Revenues (US$bn), AGR (%), CAGR (%), 2021-2031
Table 97 EU5 IBD Forecast, “U” Shaped COVID-19 Recovery: Revenues (US$bn), AGR (%), CAGR (%), 2021-2031
Table 98 EU5 IBD Forecast, “W” Shaped COVID-19 Recovery: Revenues (US$bn), AGR (%), CAGR (%), 2021-2031
Table 99 EU5 IBD Forecast, “L” Shaped COVID-19 Recovery: Revenues (US$bn), AGR (%), CAGR (%), 2021-2031
Table 100 EU5 Inflammatory Bowel Disease Drugs Market Forecast by Drug Class, 2021-2031 (US$billion, AGR%, CAGR%)
Table 101 EU5 Inflammatory Bowel Disease Drugs Market Forecast by Indication, 2021-2031 (US$billion, AGR%, CAGR%)
Table 102 EU5 Inflammatory Bowel Disease by Distribution Channel Forecast: Revenues (US$bn), AGR (%), CAGR (%), 2021-2031
Table 103 Germany IBD Forecast: Revenues (US$bn), AGR (%), CAGR (%), 2021-2031
Table 104 Germany IBD Forecast, “V” Shaped COVID-19 Recovery: Revenues (US$bn), AGR (%), CAGR (%), 2021-2031
Table 105 Germany IBD Forecast, “U” Shaped COVID-19 Recovery: Revenues (US$bn), AGR (%), CAGR (%), 2021-2031
Table 106 Germany IBD Forecast, “W” Shaped COVID-19 Recovery: Revenues (US$bn), AGR (%), CAGR (%), 2021-2031
Table 107 Germany IBD Forecast, “L” Shaped COVID-19 Recovery: Revenues (US$bn), AGR (%), CAGR (%), 2021-2031
Table 108 UK IBD Forecast: Revenues (US$bn), AGR (%), CAGR (%), 2021-2031
Table 109 UK IBD Forecast, “V” Shaped COVID-19 Recovery: Revenues (US$bn), AGR (%), CAGR (%), 2021-2031
Table 110 UK IBD Forecast, “U” Shaped COVID-19 Recovery: Revenues (US$bn), AGR (%), CAGR (%), 2021-2031
Table 111 UK IBD Forecast, “W” Shaped COVID-19 Recovery: Revenues (US$bn), AGR (%), CAGR (%), 2021-2031
Table 112 UK IBD Forecast, “L” Shaped COVID-19 Recovery: Revenues (US$bn), AGR (%), CAGR (%), 2021-2031
Table 113 France IBD Forecast: Revenues (US$bn), AGR (%), CAGR (%), 2021-2031
Table 114 France IBD Forecast, “V” Shaped COVID-19 Recovery: Revenues (US$bn), AGR (%), CAGR (%), 2021-2031
Table 115 France IBD Forecast, “U” Shaped COVID-19 Recovery: Revenues (US$bn), AGR (%), CAGR (%), 2021-2031
Table 116 France IBD Forecast, “W” Shaped COVID-19 Recovery: Revenues (US$bn), AGR (%), CAGR (%), 2021-2031
Table 117 France IBD Forecast, “L” Shaped COVID-19 Recovery: Revenues (US$bn), AGR (%), CAGR (%), 2021-2031
Table 118 Italy IBD Forecast: Revenues (US$bn), AGR (%), CAGR (%), 2021-2031
Table 119 Italy IBD Forecast, “V” Shaped COVID-19 Recovery: Revenues (US$bn), AGR (%), CAGR (%), 2021-2031
Table 120 Italy IBD Forecast, “U” Shaped COVID-19 Recovery: Revenues (US$bn), AGR (%), CAGR (%), 2021-2031
Table 121 Italy IBD Forecast, “W” Shaped COVID-19 Recovery: Revenues (US$bn), AGR (%), CAGR (%), 2021-2031
Table 122 Italy IBD Forecast, “L” Shaped COVID-19 Recovery: Revenues (US$bn), AGR (%), CAGR (%), 2021-2031
Table 123 Spain IBD Forecast: Revenues (US$bn), AGR (%), CAGR (%), 2021-2031
Table 124 Spain IBD Forecast, “V” Shaped COVID-19 Recovery: Revenues (US$bn), AGR (%), CAGR (%), 2021-2031
Table 125 Spain IBD Forecast, “U” Shaped COVID-19 Recovery: Revenues (US$bn), AGR (%), CAGR (%), 2021-2031
Table 126 Spain IBD Forecast, “W” Shaped COVID-19 Recovery: Revenues (US$bn), AGR (%), CAGR (%), 2021-2031
Table 127 Spain IBD Forecast, “L” Shaped COVID-19 Recovery: Revenues (US$bn), AGR (%), CAGR (%), 2021-2031
Table 128 BRIC IBD Drugs Market Forecast: Revenues (US$bn), AGR (%), CAGR (%), 2021-2031
Table 129 BRIC IBD Forecast, “V” Shaped COVID-19 Recovery: Revenues (US$bn), AGR (%), CAGR (%), 2021-2031
Table 130 BRIC IBD Forecast, “U” Shaped COVID-19 Recovery: Revenues (US$bn), AGR (%), CAGR (%), 2021-2031
Table 131 BRIC IBD Forecast, “W” Shaped COVID-19 Recovery: Revenues (US$bn), AGR (%), CAGR (%), 2021-2031
Table 132 BRIC IBD Forecast, “L” Shaped COVID-19 Recovery: Revenues (US$bn), AGR (%), CAGR (%), 2021-2031
Table 133 BRIC Inflammatory Bowel Disease Drugs Market Forecast by Drug Class, 2021-2031 (US$billion, AGR%, CAGR%)
Table 134 BRIC Inflammatory Bowel Disease Drugs Market Forecast by Indication, 2021-2031 (US$billion, AGR%, CAGR%)
Table 135 BRIC Inflammatory Bowel Disease by Distribution Channel Forecast: Revenues (US$bn), AGR (%), CAGR (%), 2021-2031
Table 136 Brazil IBD Forecast: Revenues (US$bn), AGR (%), CAGR (%), 2021-2031
Table 137 Brazil IBD Forecast, “V” Shaped COVID-19 Recovery: Revenues (US$bn), AGR (%), CAGR (%), 2021-2031
Table 138 Brazil IBD Forecast, “U” Shaped COVID-19 Recovery: Revenues (US$bn), AGR (%), CAGR (%), 2021-2031
Table 139 Brazil IBD Forecast, “W” Shaped COVID-19 Recovery: Revenues (US$bn), AGR (%), CAGR (%), 2021-2031
Table 140 Brazil IBD Forecast, “L” Shaped COVID-19 Recovery: Revenues (US$bn), AGR (%), CAGR (%), 2021-2031
Table 141 Russia IBD Forecast: Revenues (US$bn), AGR (%), CAGR (%), 2021-2031
Table 142 Russia IBD Forecast, “V” Shaped COVID-19 Recovery: Revenues (US$bn), AGR (%), CAGR (%), 2021-2031
Table 143 Russia IBD Forecast, “U” Shaped COVID-19 Recovery: Revenues (US$bn), AGR (%), CAGR (%), 2021-2031
Table 144 Russia IBD Forecast, “W” Shaped COVID-19 Recovery: Revenues (US$bn), AGR (%), CAGR (%), 2021-2031
Table 145 Russia IBD Forecast, “L” Shaped COVID-19 Recovery: Revenues (US$bn), AGR (%), CAGR (%), 2021-2031
Table 146 India IBD Forecast: Revenues (US$bn), AGR (%), CAGR (%), 2021-2031
Table 147 India IBD Forecast, “V” Shaped COVID-19 Recovery: Revenues (US$bn), AGR (%), CAGR (%), 2021-2031
Table 148 India IBD Forecast, “U” Shaped COVID-19 Recovery: Revenues (US$bn), AGR (%), CAGR (%), 2021-2031
Table 149 India IBD Forecast, “W” Shaped COVID-19 Recovery: Revenues (US$bn), AGR (%), CAGR (%), 2021-2031
Table 150 India IBD Forecast, “L” Shaped COVID-19 Recovery: Revenues (US$bn), AGR (%), CAGR (%), 2021-2031
Table 151 China IBD Forecast: Revenues (US$bn), AGR (%), CAGR (%), 2021-2031
Table 152 China IBD Forecast, “V” Shaped COVID-19 Recovery: Revenues (US$bn), AGR (%), CAGR (%), 2021-2031
Table 153 China IBD Forecast, “U” Shaped COVID-19 Recovery: Revenues (US$bn), AGR (%), CAGR (%), 2021-2031
Table 154 China IBD Forecast, “W” Shaped COVID-19 Recovery: Revenues (US$bn), AGR (%), CAGR (%), 2021-2031
Table 155 China IBD Forecast, “L” Shaped COVID-19 Recovery: Revenues (US$bn), AGR (%), CAGR (%), 2021-2031
Table 156 Key Patents for marketed and pipeline products, 2020
Table 157 Biologics and Biosimilars Approved for Treatment in IBD, 2020
Table 158 Biologics in the pipeline and their current status, 2020
Table 159 Biosimilars in the pipeline and their current status, 2020
Table 160 Selected IL Inhibitors in Clinical Development, 2020
Table 161 Selected CAM Inhibitors in Clinical Development, 2020
Table 162 Selected TNF-α Inhibitors in Clinical Development, 2020
Table 163 Selected Stem Cell Therapies in Clinical Development, 2020
Table 164 Selected JAK Inhibitors in Clinical Development, 2020
Table 165 Selected Toll-like Receptor Agonist in Clinical Development, 2020
Table 166 Selected Other Classes in Clinical Development, 2020
Table 167 Strategic Developments, 2017-2020
Table 168 Abbvie: Company Information, 2020
Table 169 Abbvie: Product Pipeline Information, 2020
Table 170 AbbVie Revenues (US$bn) and Market Share (%), 2020
Table 171 AbbVie: Recent Developments, 2017-2020
Table 172 Janssen Biotech: Company Information, 2020
Table 173 Janssen Biotech Revenues (US$Mn) and Market Share (%), 2020
Table 174 Janssen Biotech Revenues (US$Mn) and Market Share (%), 2020
Table 175 Jassen Biotech: Recent Developments, 2017-2020
Table 176 Allergen plc: Company Information, 2020
Table 177 Allergan Revenues (US$bn) and Market Share (%), 2020
Table 178 Allergan Plc: Recent Developments, 2017-2020
Table 179 Takeda: Company Information, 2020
Table 180 Takeda Revenues (US$bn) and Market Share (%), 2020
Table 181 Takeda Pharmaceuticals: Recent Developments, 2017-2020
Table 182 Pfizer plc: Company Information, 2020
Table 183 Pfizer Revenues (US$bn) and Market Share (%), 2020
Table 184 Pfizer: Recent Developments, 2017-2020
Table 185 Novartis AG: Company Information, 2020
Table 186 Novartis AG: Recent Developments, 2017-2020
Table 187 UCB: Company Information, 2020
Table 188 UCB Pharma S.A Revenues (US$bn) and Market Share (%), 2020
Table 189 Biogen: Company Information, 2020
Table 190 Biogen Inc. Revenues (US$bn) and Market Share (%), 2020
Table 191 Gilead: Company Information, 2020
Table 192 Roche: Company Information, 2020
Table 193 Roche: Recent Developments, 2017-2020
Table 194 Celgene: Company Information, 2020
Table 195 Celgene Corp.: Recent Developments, 2017-2020
Table 196 Celltrion: Company Information, 2020
Table 197 Ferring B.V.: Company Information, 2020
Table 198 Global IBD Revenue Forecasts (US$bn), Market Share (%) by Product Category, 2020, 2026, 2031
Table 199 Global IBD Revenue Forecasts (US$bn) and Market Shares (%) by Region, 2020, 2026, 2031
List of Figures
Figure 1 Global Inflammatory Bowel Disease Drugs Market Segmentation
Figure 2 Global IBD Drugs Market Drivers and Restraints 2021-2031
Figure 3 Porter’s Five Forces Analysis
Figure 4 SWOT Analysis
Figure 5 PEST Analysis
Figure 6 Global Inflammatory Bowel Disease Drugs Market, Revenue Forecast 2021-2031 (US$billion, AGR%)
Figure 7 “V” Shaped Recovery: Global Inflammatory Bowel Disease Drugs Market, Revenue Forecast 2021-2031 (US$billion, AGR%)
Figure 8 “U” Shaped Recovery: Global Inflammatory Bowel Disease Drugs Market, Revenue Forecast 2021-2031 (US$billion, AGR%)
Figure 9 “W” Shaped Recovery: Global Inflammatory Bowel Disease Drugs Market, Revenue Forecast 2021-2031 (US$billion, AGR%)
Figure 10 “L” Shaped Recovery: Global Inflammatory Bowel Disease Drugs Market, Revenue Forecast 2021-2031 (US$billion, AGR%)
Figure 11 Global Inflammatory Bowel Disease Drugs Market Forecast by Indication, 2021, 2026, & 2031 (US$billion)
Figure 12 Global Inflammatory Bowel Disease Drugs Market Share Forecast by Indication, 2021, 2026, 2031 (%)
Figure 13 Global Inflammatory Bowel Disease Drugs Market for Crohn’s Disease Segment: Revenue Forecast 2021-2031 (US$billion, AGR%)
Figure 14 “V” Shaped Recovery: Global Inflammatory Bowel Disease Drugs Market for Crohn’s Disease Segment, Revenue Forecast 2021-2031 (US$billion, AGR%)
Figure 15 “U” Shaped Recovery: Global Inflammatory Bowel Disease Drugs Market for Crohn’s Disease Segment, Revenue Forecast 2021-2031 (US$billion, AGR%)
Figure 16 “W” Shaped Recovery: Global Inflammatory Bowel Disease Drugs Market for Crohn’s Disease Segment, Revenue Forecast 2021-2031 (US$billion, AGR%)
Figure 17 “L” Shaped Recovery: Global Inflammatory Bowel Disease Drugs Market for Crohn’s Disease Segment, Revenue Forecast 2021-2031 (US$billion, AGR%)
Figure 18 Global Inflammatory Bowel Disease Drugs Market for Ulcerative Colitis Segment: Revenue Forecast 2021-2031 (US$billion, AGR%)
Figure 19 “V” Shaped Recovery: Global Inflammatory Bowel Disease Drugs Market for Ulcerative Colitis Segment, Revenue Forecast 2021-2031 (US$billion, AGR%)
Figure 20 “U” Shaped Recovery: Global Inflammatory Bowel Disease Drugs Market for Ulcerative Colitis Segment, Revenue Forecast 2021-2031 (US$billion, AGR%)
Figure 21 “W” Shaped Recovery: Global Inflammatory Bowel Disease Drugs Market for Ulcerative Colitis Segment, Revenue Forecast 2021-2031 (US$billion, AGR%)
Figure 22 “L” Shaped Recovery: Global Inflammatory Bowel Disease Drugs Market for Ulcerative Colitis Segment, Revenue Forecast 2021-2031 (US$billion, AGR%)
Figure 23 Global Biologic Therapies Drivers and Restraints, 2021-2031
Figure 24 Global Inflammatory Bowel Disease Drugs Market for Biologics Segment: Revenue Forecast 2021-2031 (US$billion, AGR%)
Figure 25 “V” Shaped Recovery: Global Inflammatory Bowel Disease Drugs Market for Biologics Segment, Revenue Forecast 2021-2031 (US$billion, AGR%)
Figure 26 “U” Shaped Recovery: Global Inflammatory Bowel Disease Drugs Market for Biologics Segment, Revenue Forecast 2021-2031 (US$billion, AGR%)
Figure 27 “W” Shaped Recovery: Global Inflammatory Bowel Disease Drugs Market for Biologics Segment, Revenue Forecast 2021-2031 (US$billion, AGR%)
Figure 28 “L” Shaped Recovery: Global Inflammatory Bowel Disease Drugs Market for Biologics Segment, Revenue Forecast 2021-2031 (US$billion, AGR%)
Figure 29 Global Aminosalicylates Drivers and Restraints, 2021-2031
Figure 30 Global Inflammatory Bowel Disease Drugs Market for Aminosalicylates Segment: Revenue Forecast 2021-2031 (US$billion, AGR%)
Figure 31 “V” Shaped Recovery: Global Inflammatory Bowel Disease Drugs Market for Aminosalicylates Segment, Revenue Forecast 2021-2031 (US$billion, AGR%)
Figure 32 “U” Shaped Recovery: Global Inflammatory Bowel Disease Drugs Market for Aminosalicylates Segment, Revenue Forecast 2021-2031 (US$billion, AGR%)
Figure 33 “W” Shaped Recovery: Global Inflammatory Bowel Disease Drugs Market for Aminosalicylates Segment, Revenue Forecast 2021-2031 (US$billion, AGR%)
Figure 34 “L” Shaped Recovery: Global Inflammatory Bowel Disease Drugs Market for Aminosalicylates Segment, Revenue Forecast 2021-2031 (US$billion, AGR%)
Figure 35 Global Corticosteroids Drivers and Restraints, 2021-2031
Figure 36 Global Inflammatory Bowel Disease Drugs Market for Corticosteroids Segment: Revenue Forecast 2021-2031 (US$billion, AGR%)
Figure 37 “V” Shaped Recovery: Global Inflammatory Bowel Disease Drugs Market for Corticosteroids Segment, Revenue Forecast 2021-2031 (US$billion, AGR%)
Figure 38 “U” Shaped Recovery: Global Inflammatory Bowel Disease Drugs Market for Corticosteroids Segment, Revenue Forecast 2021-2031 (US$billion, AGR%)
Figure 39 “W” Shaped Recovery: Global Inflammatory Bowel Disease Drugs Market for Corticosteroids Segment, Revenue Forecast 2021-2031 (US$billion, AGR%)
Figure 40 “L” Shaped Recovery: Global Inflammatory Bowel Disease Drugs Market for Corticosteroids Segment, Revenue Forecast 2021-2031 (US$billion, AGR%)
Figure 41 Global Antibiotics Drivers and Restraints, 2021-2031
Figure 42 Global Inflammatory Bowel Disease Drugs Market for Antibiotics Segment: Revenue Forecast 2021-2031 (US$billion, AGR%)
Figure 43 “V” Shaped Recovery: Global Inflammatory Bowel Disease Drugs Market for Antibiotics Segment, Revenue Forecast 2021-2031 (US$billion, AGR%)
Figure 44 “U” Shaped Recovery: Global Inflammatory Bowel Disease Drugs Market for Antibiotics Segment, Revenue Forecast 2021-2031 (US$billion, AGR%)
Figure 45 “W” Shaped Recovery: Global Inflammatory Bowel Disease Drugs Market for Antibiotics Segment, Revenue Forecast 2021-2031 (US$billion, AGR%)
Figure 46 “L” Shaped Recovery: Global Inflammatory Bowel Disease Drugs Market for Antibiotics Segment, Revenue Forecast 2021-2031 (US$billion, AGR%)
Figure 47 Global Immunomodulators Drivers and Restraints, 2021-2031
Figure 48 Global Inflammatory Bowel Disease Drugs Market for Immunomodulators Segment: Revenue Forecast 2021-2031 (US$billion, AGR%)
Figure 49 “V” Shaped Recovery: Global Inflammatory Bowel Disease Drugs Market for Immunomodulators Segment, Revenue Forecast 2021-2031 (US$billion, AGR%)
Figure 50 “U” Shaped Recovery: Global Inflammatory Bowel Disease Drugs Market for Immunomodulators Segment, Revenue Forecast 2021-2031 (US$billion, AGR%)
Figure 51 “W” Shaped Recovery: Global Inflammatory Bowel Disease Drugs Market for Immunomodulators Segment, Revenue Forecast 2021-2031 (US$billion, AGR%)
Figure 52 “L” Shaped Recovery: Global Inflammatory Bowel Disease Drugs Market for Immunomodulators Segment, Revenue Forecast 2021-2031 (US$billion, AGR%)
Figure 53 Global Inflammatory Bowel Disease Drugs Market for Others Segment: Revenue Forecast 2021-2031 (US$billion, AGR%)
Figure 54 “V” Shaped Recovery: Global Inflammatory Bowel Disease Drugs Market for Others Segment, Revenue Forecast 2021-2031 (US$billion, AGR%)
Figure 55 “U” Shaped Recovery: Global Inflammatory Bowel Disease Drugs Market for Others Segment, Revenue Forecast 2021-2031 (US$billion, AGR%)
Figure 56 “W” Shaped Recovery: Global Inflammatory Bowel Disease Drugs Market for Others Segment, Revenue Forecast 2021-2031 (US$billion, AGR%)
Figure 57 “L” Shaped Recovery: Global Inflammatory Bowel Disease Drugs Market for Others Segment, Revenue Forecast 2021-2031 (US$billion, AGR%)
Figure 58 Global Inflammatory Bowel Disease Drugs Market for Hospital Pharmacies Segment: Revenue Forecast 2021-2031 (US$billion, AGR%)
Figure 59 “V” Shaped Recovery: Global Inflammatory Bowel Disease Drugs Market for Hospital Pharmacies Segment, Revenue Forecast 2021-2031 (US$billion, AGR%)
Figure 60 “U” Shaped Recovery: Global Inflammatory Bowel Disease Drugs Market for Hospital Pharmacies Segment, Revenue Forecast 2021-2031 (US$billion, AGR%)
Figure 61 “W” Shaped Recovery: Global Inflammatory Bowel Disease Drugs Market for Hospital Pharmacies Segment, Revenue Forecast 2021-2031 (US$billion, AGR%)
Figure 62 “L” Shaped Recovery: Global Inflammatory Bowel Disease Drugs Market for Hospital Pharmacies Segment, Revenue Forecast 2021-2031 (US$billion, AGR%)
Figure 63 Global Inflammatory Bowel Disease Drugs Market for Retail Pharmacies Segment: Revenue Forecast 2021-2031 (US$billion, AGR%)
Figure 64 “V” Shaped Recovery: Global Inflammatory Bowel Disease Drugs Market for Retail Pharmacies Segment, Revenue Forecast 2021-2031 (US$billion, AGR%)
Figure 65 “U” Shaped Recovery: Global Inflammatory Bowel Disease Drugs Market for Retail Pharmacies Segment, Revenue Forecast 2021-2031 (US$billion, AGR%)
Figure 66 “W” Shaped Recovery: Global Inflammatory Bowel Disease Drugs Market for Retail Pharmacies Segment, Revenue Forecast 2021-2031 (US$billion, AGR%)
Figure 67 “L” Shaped Recovery: Global Inflammatory Bowel Disease Drugs Market for Retail Pharmacies Segment, Revenue Forecast 2021-2031 (US$billion, AGR%)
Figure 68 Global Inflammatory Bowel Disease Drugs Market for Online Pharmacies Segment: Revenue Forecast 2021-2031 (US$billion, AGR%)
Figure 69 “V” Shaped Recovery: Global Inflammatory Bowel Disease Drugs Market for Online Pharmacies Segment, Revenue Forecast 2021-2031 (US$billion, AGR%)
Figure 70 “U” Shaped Recovery: Global Inflammatory Bowel Disease Drugs Market for Online Pharmacies Segment, Revenue Forecast 2021-2031 (US$billion, AGR%)
Figure 71 “W” Shaped Recovery: Global Inflammatory Bowel Disease Drugs Market for Online Pharmacies Segment, Revenue Forecast 2021-2031 (US$billion, AGR%)
Figure 72 “L” Shaped Recovery: Global Inflammatory Bowel Disease Drugs Market for Online Pharmacies Segment, Revenue Forecast 2021-2031 (US$billion, AGR%)
Figure 73 Figure 60: Global IBD Drugs Market by Region (%), 2021, 2026, & 2031
Figure 74 Figure 60: Global IBD Drugs Market by Region (%), 2021, 2026, & 2031
Figure 75 US IBD Drugs Market Forecast (US$bn), AGR (%), 2021-2031
Figure 76 US Inflammatory Bowel Disease Drugs Market Forecast, “V” Shaped COVID-19 Recovery (US$bn), AGR (%), 2021-2031
Figure 77 US IBD Forecast, “U” Shaped COVID-19 Recovery (US$bn), AGR (%), 2021-2031
Figure 78 US Inflammatory Bowel Disease Drugs Market Forecast, “W” Shaped COVID-19 Recovery (US$bn), AGR (%), 2021-2031
Figure 79 US Inflammatory Bowel Disease Drugs Market Forecast, “L” Shaped COVID-19 Recovery (US$bn), AGR (%), 2021-2031
Figure 80 Japanese IBD Drugs Market Forecast (US$bn), AGR (%), 2021-2031
Figure 81 Japan Inflammatory Bowel Disease Drugs Market Forecast, “V” Shaped COVID-19 Recovery (US$bn), AGR (%), 2021-2031
Figure 82 Japan IBD Forecast, “U” Shaped COVID-19 Recovery (US$bn), AGR (%), 2021-2031
Figure 83 Japan Inflammatory Bowel Disease Drugs Market Forecast, “W” Shaped COVID-19 Recovery (US$bn), AGR (%), 2021-2031
Figure 84 Japan Inflammatory Bowel Disease Drugs Market Forecast, “L” Shaped COVID-19 Recovery (US$bn), AGR (%), 2021-2031
Figure 85 EU5 IBD Drugs Market Forecast (US$bn), AGR (%), 2021-2031
Figure 86 EU5 Inflammatory Bowel Disease Drugs Market Forecast, “V” Shaped COVID-19 Recovery (US$bn), AGR (%), 2021-2031
Figure 87 EU5 IBD Forecast, “U” Shaped COVID-19 Recovery (US$bn), AGR (%), 2021-2031
Figure 88 EU5 Inflammatory Bowel Disease Drugs Market Forecast, “W” Shaped COVID-19 Recovery (US$bn), AGR (%), 2021-2031
Figure 89 EU5 Inflammatory Bowel Disease Drugs Market Forecast, “L” Shaped COVID-19 Recovery (US$bn), AGR (%), 2021-2031
Figure 90 Germany Inflammatory Bowel Disease Drugs Market Forecast (US$bn), AGR (%), 2021-2031
Figure 91 Germany Inflammatory Bowel Disease Drugs Market Forecast, “V” Shaped COVID-19 Recovery (US$bn), AGR (%), 2021-2031
Figure 92 Germany IBD Forecast, “U” Shaped COVID-19 Recovery (US$bn), AGR (%), 2021-2031
Figure 93 Germany Inflammatory Bowel Disease Drugs Market Forecast, “W” Shaped COVID-19 Recovery (US$bn), AGR (%), 2021-2031
Figure 94 Germany Inflammatory Bowel Disease Drugs Market Forecast, “L” Shaped COVID-19 Recovery (US$bn), AGR (%), 2021-2031
Figure 95 UK Inflammatory Bowel Disease Drugs Market Forecast (US$bn), AGR (%), 2021-2031
Figure 96 UK Inflammatory Bowel Disease Drugs Market Forecast, “V” Shaped COVID-19 Recovery (US$bn), AGR (%), 2021-2031
Figure 97 UK IBD Forecast, “U” Shaped COVID-19 Recovery (US$bn), AGR (%), 2021-2031
Figure 98 UK Inflammatory Bowel Disease Drugs Market Forecast, “W” Shaped COVID-19 Recovery (US$bn), AGR (%), 2021-2031
Figure 99 UK Inflammatory Bowel Disease Drugs Market Forecast, “L” Shaped COVID-19 Recovery (US$bn), AGR (%), 2021-2031
Figure 100 France Inflammatory Bowel Disease Drugs Market Forecast, (US$bn), AGR (%), 2021-2031
Figure 101 France Inflammatory Bowel Disease Drugs Market Forecast, “V” Shaped COVID-19 Recovery (US$bn), AGR (%), 2021-2031
Figure 102 France IBD Forecast, “U” Shaped COVID-19 Recovery (US$bn), AGR (%), 2021-2031
Figure 103 France Inflammatory Bowel Disease Drugs Market Forecast, “W” Shaped COVID-19 Recovery (US$bn), AGR (%), 2021-2031
Figure 104 France Inflammatory Bowel Disease Drugs Market Forecast, “L” Shaped COVID-19 Recovery (US$bn), AGR (%), 2021-2031
Figure 105 Italy Inflammatory Bowel Disease Drugs Market Forecast (US$bn), AGR (%), 2021-2031
Figure 106 Italy Inflammatory Bowel Disease Drugs Market Forecast, “V” Shaped COVID-19 Recovery (US$bn), AGR (%), 2021-2031
Figure 107 Italy IBD Forecast, “U” Shaped COVID-19 Recovery (US$bn), AGR (%), 2021-2031
Figure 108 Italy Inflammatory Bowel Disease Drugs Market Forecast, “W” Shaped COVID-19 Recovery (US$bn), AGR (%), 2021-2031
Figure 109 Italy Inflammatory Bowel Disease Drugs Market Forecast, “L” Shaped COVID-19 Recovery (US$bn), AGR (%), 2021-2031
Figure 110 Spain Inflammatory Bowel Disease Drugs Market Forecast (US$bn), AGR (%), 2021-2031
Figure 111 Spain Inflammatory Bowel Disease Drugs Market Forecast, “V” Shaped COVID-19 Recovery (US$bn), AGR (%), 2021-2031
Figure 112 Spain IBD Forecast, “U” Shaped COVID-19 Recovery (US$bn), AGR (%), 2021-2031
Figure 113 Spain Inflammatory Bowel Disease Drugs Market Forecast, “W” Shaped COVID-19 Recovery (US$bn), AGR (%), 2021-2031
Figure 114 Spain Inflammatory Bowel Disease Drugs Market Forecast, “L” Shaped COVID-19 Recovery (US$bn), AGR (%), 2021-2031
Figure 115 BRIC IBD Drugs Market Forecast (US$bn), AGR (%), 2021-2031
Figure 116 BRIC Inflammatory Bowel Disease Drugs Market Forecast, “V” Shaped COVID-19 Recovery (US$bn), AGR (%), 2021-2031
Figure 117 BRIC IBD Forecast, “U” Shaped COVID-19 Recovery (US$bn), AGR (%), 2021-2031
Figure 118 BRIC Inflammatory Bowel Disease Drugs Market Forecast, “W” Shaped COVID-19 Recovery (US$bn), AGR (%), 2021-2031
Figure 119 EU5 Inflammatory Bowel Disease Drugs Market Forecast, “L” Shaped COVID-19 Recovery (US$bn), AGR (%), 2021-2031
Figure 120 Brazil Inflammatory Bowel Disease Drugs Market Forecast (US$bn), AGR (%), 2021-2031
Figure 121 Brazil Inflammatory Bowel Disease Drugs Market Forecast, “V” Shaped COVID-19 Recovery (US$bn), AGR (%), 2021-2031
Figure 122 Brazil IBD Forecast, “U” Shaped COVID-19 Recovery (US$bn), AGR (%), 2021-2031
Figure 123 Brazil Inflammatory Bowel Disease Drugs Market Forecast, “W” Shaped COVID-19 Recovery (US$bn), AGR (%), 2021-2031
Figure 124 Brazil Inflammatory Bowel Disease Drugs Market Forecast, “L” Shaped COVID-19 Recovery (US$bn), AGR (%), 2021-2031
Figure 125 Russia Inflammatory Bowel Disease Drugs Market Forecast (US$bn), AGR (%), 2021-2031
Figure 126 Russia Inflammatory Bowel Disease Drugs Market Forecast, “V” Shaped COVID-19 Recovery (US$bn), AGR (%), 2021-2031
Figure 127 Russia IBD Forecast, “U” Shaped COVID-19 Recovery (US$bn), AGR (%), 2021-2031
Figure 128 Russia Inflammatory Bowel Disease Drugs Market Forecast, “W” Shaped COVID-19 Recovery (US$bn), AGR (%), 2021-2031
Figure 129 Russia Inflammatory Bowel Disease Drugs Market Forecast, “L” Shaped COVID-19 Recovery (US$bn), AGR (%), 2021-2031
Figure 130 India Inflammatory Bowel Disease Drugs Market Forecast (US$bn), AGR (%), 2021-2031
Figure 131 India Inflammatory Bowel Disease Drugs Market Forecast, “V” Shaped COVID-19 Recovery (US$bn), AGR (%), 2021-2031
Figure 132 India IBD Forecast, “U” Shaped COVID-19 Recovery (US$bn), AGR (%), 2021-2031
Figure 133 India Inflammatory Bowel Disease Drugs Market Forecast, “W” Shaped COVID-19 Recovery (US$bn), AGR (%), 2021-2031
Figure 134 India Inflammatory Bowel Disease Drugs Market Forecast, “L” Shaped COVID-19 Recovery (US$bn), AGR (%), 2021-2031
Figure 135 China Inflammatory Bowel Disease Drugs Market Forecast (US$bn), AGR (%), 2021-2031
Figure 136 China Inflammatory Bowel Disease Drugs Market Forecast, “V” Shaped COVID-19 Recovery (US$bn), AGR (%), 2021-2031
Figure 137 China IBD Forecast, “U” Shaped COVID-19 Recovery (US$bn), AGR (%), 2021-2031
Figure 138 China Inflammatory Bowel Disease Drugs Market Forecast, “W” Shaped COVID-19 Recovery (US$bn), AGR (%), 2021-2031
Figure 139 China Inflammatory Bowel Disease Drugs Market Forecast, “L” Shaped COVID-19 Recovery (US$bn), AGR (%), 2021-2031
Figure 140 Global Inflammatory Bowel Disease Drugs Market: Company Share Analysis, 2020
Figure 141 Janssen Assets – Marketed and Pipeline 2019
Figure 142 Allergan Assets – Marketed and Pipeline 2019
Figure 143 Takeda Assets – Marketed and Pipeline 2019
Figure 144 Takeda - Major Areas: ~75% of Total Sales Concentrated in Five Areas
Figure 145 Pfizer Overall Assets – Marketed and Pipeline 2019
Figure 146 Novartis AG Assets – Marketed and Pipeline
Figure 147 UCB Pharma Assets – Marketed and Pipeline 2019
Companies Profiled in the Report
AbbVie
Allergan plc
Biogen Inc.
Celgene Corporation
Celltrion Corporation
Ferring B.V.
Gilead Sciences, Inc.
Janssen Biotech
Novartis AG
Pfizer Inc.
Roche
Takeda Pharmaceuticals
UCB Pharma S.A.
List of Companies Mentioned in the Report
4SC
Abbvie
Ablynx
Active Biotech
Ajinomoto
Allergan plc
Amgen
AstraZeneca
Athersys Inc.
Atlantic Healthcare
Avaxia Biologics
Biogen Inc.
BiomX Ltd
BiomX Ltd BioLine RX
Boehringer Ingelheim
Celgene Cellular Therapeutics
Celgene Corporation
Celltrion Corporation
Centocor
Coronado Biosciences
CyCol
Dr. Falk Pharma
Ferring B.V.
Galapagos
Gilead Sciences, Inc.
Harbor BioSciences
InDex Pharmaceuticals
Isis Pharmaceuticals
J&J
Janssen Biotech
MedImmune Ltd
Neovacs
Novartis AG
Osiris Therapeutics
Otsuka
Pfizer Inc.
Pharmascience Inc.
Receptos
RedHill Biopharma
Roche
Scripps Research
Sequella
Servicio Sanitario Nazionale (SSN)
Sigmoid Pharma Limited
Soligenix
Sublimity Therapeutics Pendopharm
Takeda Pharmaceuticals
TiGenix
TxCell
UCB Pharma S.A.
List of Organizations Mentioned in the Report
Agencia Nacional de Vigiloncia Sanitaria (ANVISA)
American Gastroenterological Association
Centers for Disease Control and Prevention (CDC)
Central Drug Standard Control Organization (CDSCO)
Centre for Pharmaceutical Administration Health Sciences Authority
Crohn’s and Colitis Foundation of Canada
Departamento de Economia
ECCO-Epicom group
Economic Cooperation and Development (OECD)
European Commission
European Crohn’s and Colitis Organisation (ECCO)
European Federation of Crohn's and Ulcerative Colitis Associations
Food and Drug Administration (FDA)
German Society of Gastroenterology (DGVS)
Global Burden of Diseases (GBD)
Japanese Ministry of Health, Labour and Welfare
Medicines and Healthcare Products Regulatory Agency (MHRA)
Ministry of Health of the Russian Federation
Ministry of Health, Labour & Welfare (MHLW)
National Institutes of Health (NIH)
NCBI
World Bank
World Health Organization (WHO)
Visiongain Pharma
Visiongain Pharma
Visiongain Pharma
